¼¼°èÀÇ µÎ°æºÎ¾Ï Áø´Ü ½ÃÀå
Head and Neck Cancer Diagnostics
»óǰÄÚµå : 1577495
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 296 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

µÎ°æºÎ¾Ï Áø´Ü ¼¼°è ½ÃÀåÀº 2030³â±îÁö 152¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸Á

2023³â 68¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â µÎ°æºÎ¾Ï Áø´Ü ¼¼°è ½ÃÀåÀº 2023-2030³â ºÐ¼® ±â°£ µ¿¾È ¿¬Æò±Õ 12.1% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 152¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ »ý°Ë ¹× Ç÷¾× °Ë»ç´Â CAGR 13.0%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 62¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿µ»ó Áø´Ü ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 12.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀå 19¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 16.5%·Î ¼ºÀå Àü¸Á

¹Ì±¹ÀÇ µÎ°æºÎ¾Ï Áø´Ü ½ÃÀåÀº 2023³â 19¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 33¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³â ºÐ¼® ±â°£ µ¿¾È 16.5%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 9.0%¿Í 10.6%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¿¬Æò±Õ 9.6%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è µÎ°æºÎ¾Ï Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

µÎ°æºÎ¾Ï Áø´Ü ±â¼úÀº ¾î¶»°Ô µÎ°æºÎ¾ÏÀ» ¹ß°ßÇÒ ¼ö ÀÖÀ»±î?

Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î µÎ°æºÎ¾ÏÀ» Á¶±â¿¡ Á¤È®ÇÏ°Ô ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¿µ»ó Áø´Ü, »ý°Ë, ºÐÀÚ °Ë»ç µî ÃֽŠÁø´Ü ±â¼úÀº µÎ°æºÎ¾ÏÀ» Á¶±â¿¡ ¹ß°ßÇÏ´Â ´É·ÂÀ» Å©°Ô Çâ»ó½ÃÄÑ È¯ÀÚÀÇ ¿¹Èĸ¦ Å©°Ô °³¼±ÇßÀ¸¸ç, PET, MRI, CT ½ºÄµ°ú °°Àº ¿µ»ó Áø´Ü ±â¼úÀº Á¾¾çÀ» ½Äº°ÇÏ°í ¸ð´ÏÅ͸µÇÏ´Â µ¥ ³Î¸® »ç¿ëµÇ¾î ¾ÏÀÌ ÆÛÁø À§Ä¡¿Í ¹üÀ§¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ¾ÏÀÇ È®»ê À§Ä¡¿Í ¹üÀ§¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ºÐÀÚÁø´ÜÇÐÀº ÀÌ·¯ÇÑ ¾Ï°ú °ü·ÃµÈ ƯÁ¤ À¯ÀüÀÚ µ¹¿¬º¯ÀÌ ¹× ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°ÇÔÀ¸·Î½á µÎ°æºÎ¾Ï Áø´ÜÀÇ ÆÇµµ¸¦ ¹Ù²Ù°í ÀÖ½À´Ï´Ù. Ç÷¾× ³» ¼øÈ¯ Á¾¾ç DNA¸¦ °ËÃâÇÒ ¼ö ÀÖ´Â ¾×ü »ý°Ë°ú °°Àº Ä¡·á ±â¼úÀº ±âÁ¸ÀÇ Á¶Á÷ »ý°ËÀ» ´ëüÇÒ ¼ö ÀÖ´Â ´ú ħ½ÀÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÏ¿© Á¶±â ¹ß°ß°ú º¸´Ù ¸ÂÃãÈ­µÈ Ä¡·á ¿É¼ÇÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ ¹ßÀüÀº Áø´ÜÀÇ Á¤È®¼ºÀ» ³ôÀ̰í, ÀÓ»óÀǰ¡ ȯÀÚ °³°³Àο¡°Ô °¡Àå ÀûÇÕÇÑ Ä¡·á¹ýÀ» ¼±ÅÃÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÖ¸ç, ±× °úÁ¤¿¡¼­ »ýÁ¸À²µµ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

µÎ°æºÎ¾Ï Áø´ÜÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â Çõ½ÅÀº ¹«¾ùÀϱî?

±â¼ú Çõ½ÅÀº µÎ°æºÎ¾Ï Áø´ÜÀÇ ÁøÈ­¸¦ ÃËÁøÇÏ¿© ¾ÏÀ» Á¶±â¿¡ ¹ß°ßÇϰí ȯÀÚ °³°³ÀÎÀÇ Çʿ信 ¸Â´Â Ä¡·á¸¦ ¿ëÀÌÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. Áß¿äÇÑ ¹ßÀü Áß Çϳª´Â Á¾¾çÀÇ À¯ÀüÀÚ µ¹¿¬º¯ÀÌ¿Í ÀÌ»óÀ» Æ÷°ýÀûÀ¸·Î ºÐ¼®ÇÒ ¼ö ÀÖ´Â Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS) ±â¼úÀÇ µîÀåÀ¸·Î, NGS´Â ¾ÏÀÇ ºÐÀÚ ÇÁ·ÎÆÄÀÏ¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸¸¦ Á¦°øÇÏ¿© Àǻ簡 ´Ù¾çÇÑ Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀÀ» ¿¹ÃøÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. ¶Ç ´Ù¸¥ ÁÖ¿ä Çõ½ÅÀº ÀΰøÁö´É(AI) ±â¹Ý Áø´Ü µµ±¸·Î, ÀÓ»óÀǰ¡ ¿µ»ó Áø´Ü °á°ú¿Í À¯ÀüÀÚ Á¤º¸¸¦ Æ÷ÇÔÇÑ º¹ÀâÇÑ µ¥ÀÌÅÍ ¼¼Æ®¸¦ ºÐ¼®ÇÏ¿© ÀÓ»óÀǰ¡ ´õ ºü¸£°í Á¤È®ÇÑ Áø´ÜÀ» ³»¸± ¼ö ÀÖµµ·Ï µ½±â À§ÇØ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ AI ±â¹Ý ½Ã½ºÅÛÀº »ç¶÷ÀÇ ´«À¸·Î´Â °£°úÇÒ ¼ö ÀÖ´Â ÆÐÅÏÀ» °¨ÁöÇÒ ¼ö ÀÖ¾î ¾Ç¼º Á¾¾çÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀå¿¡¼­ ½Å¼ÓÇÏ°Ô °Ë»çÇÒ ¼ö ÀÖ´Â ÇöÀå Áø´ÜÀº ƯÈ÷ ÷´Ü ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑÀûÀÎ Áö¿ª¿¡¼­ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ ºñ¾àÀûÀÎ ¹ßÀüÀº µÎ°æºÎ¾Ï Áø´ÜÀ» º¸´Ù °³ÀÎÈ­µÇ°í È¿À²ÀûÀÎ ÀÇ·á ¼­ºñ½º·Î ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù.

¼ÒºñÀÚ ¹× ÇコÄÉ¾î Æ®·»µåÀÇ º¯È­°¡ µÎ°æºÎ¾Ï Áø´Ü ¼ö¿ä¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

¼ÒºñÀÚ Àǽİú ÇコÄÉ¾î Æ®·»µå´Â µÎ°æºÎ¾Ï Áø´Ü ¼ö¿ä Çü¼º¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¹æÀÇÇп¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­, ƯÈ÷ Èí¿¬ÀÚ³ª ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °¨¿°ÀÚ µî °íÀ§Ç豺µéÀº µÎ°æºÎ¾Ï °ËÁøÀ» Àû±ØÀûÀ¸·Î ¹Þ°í ÀÖ½À´Ï´Ù. Á¶±â ¹ß°ß°ú ´ã¹èÀÇ À§Ç輺¿¡ ´ëÇÑ ÀÎ½Ä °³¼± Ä·ÆäÀÎÀÌ È°¹ßÇØÁö¸é¼­, ƯÈ÷ ÀÇ·á ½Ã½ºÅÛÀÌ Àß °®ÃçÁø ¼±Áø±¹¿¡¼­´Â Áø´Ü ¼­ºñ½º¸¦ ¹Þ´Â »ç¶÷ÀÌ ´Ã°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µÎ°æºÎ¾ÏÀº ³ë³âÃþ¿¡¼­ ¸¹ÀÌ ¹ß»ýÇϱ⠶§¹®¿¡ Àü ¼¼°èÀûÀ¸·Î °í·ÉÈ­°¡ µÎ°æºÎ¾Ï ȯÀÚ Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°øÀÚµéÀÌ È¯ÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí Ä¡·á ºñ¿ëÀ» Àý°¨Çϱâ À§ÇØ Á¶±â Áø´Ü¿¡ ÁßÁ¡À» µÎ¸é¼­ Á¾ÇÕÀûÀÎ Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

µÎ°æºÎ¾Ï Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀϱî?

µÎ°æºÎ¾Ï Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ¾Ï ¹ßº´·ü Áõ°¡, ÀÇ·á Á¤Ã¥ÀÇ ¹ßÀü°ú °ü·ÃµÈ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â ¾×ü »ý°Ë, Â÷¼¼´ë ½ÃÄö½Ì, AI ±â¹Ý À̹Ì¡°ú °°Àº ÷´Ü Áø´Ü ±â¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾ÏÀ» Á¶±â¿¡ Á¤È®ÇÏ°Ô ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú´Ù´Â Á¡ÀÔ´Ï´Ù. ¶ÇÇÑ, µÎ°æºÎ¾Ï, ƯÈ÷ HPV¿Í °ü·ÃµÈ ¾Ï ¹ßº´·üÀÇ Áõ°¡·Î ÀÎÇØ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿Í Á¤ºÎ°¡ °ËÁø¿¡ ÁýÁßÇϰí ÀÖ´Â °Íµµ ½ÃÀå ±Ô¸ð¸¦ È®´ëÇÏ´Â ¿äÀÎÀÔ´Ï´Ù. º´¿ø, Áø´Ü¼¾ÅÍ, ¿¬±¸±â°üÀÌ Á¤È®ÇÏ°í ºñħ½ÀÀûÀÎ ¾Ï °ËÁø¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ ÀÌ·¯ÇÑ ±â¼úÀ» äÅÃÇÔ¿¡ µû¶ó ÃÖÁ¾ ¿ëµµ°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚÀÇ Á¾¾ç À¯ÀüÀû ±¸¼º¿¡ µû¶ó Ä¡·á °èȹÀ» ¼¼¿ì´Â °³ÀÎ ¸ÂÃãÇü ÀÇ·á·ÎÀÇ ÀüȯÀ¸·Î ºÐÀÚÁø´ÜÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¾ÏÀÇ Á¶±â ¹ß°ßÀ» ÃËÁøÇÏ´Â ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í ¼¼°è ÇコÄɾî ÁöÃâ Áõ°¡´Â ÷´Ü Áø´Ü ±â¼úÀÇ Ã¤ÅÃÀ» ´õ¿í °¡¼ÓÈ­ÇÏ¿© ÀÌ ½ÃÀåÀ» È®´ëÇÏ°í ºü¸£°Ô ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 53°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Head and Neck Cancer Diagnostics Market to Reach US$15.2 Billion by 2030

The global market for Head and Neck Cancer Diagnostics estimated at US$6.8 Billion in the year 2023, is expected to reach US$15.2 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2023-2030. Biopsy & Blood Tests, one of the segments analyzed in the report, is expected to record a 13.0% CAGR and reach US$6.2 Billion by the end of the analysis period. Growth in the Imaging segment is estimated at 12.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 16.5% CAGR

The Head and Neck Cancer Diagnostics market in the U.S. is estimated at US$1.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2030 trailing a CAGR of 16.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.0% and 10.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR.

Global Head and Neck Cancer Diagnostics Market - Key Trends & Drivers Summarized

How Are Diagnostic Technologies Advancing the Detection of Head and Neck Cancer?

The early and accurate detection of head and neck cancer is becoming increasingly achievable thanks to advancements in diagnostic technologies. Modern diagnostic techniques, including imaging, biopsies, and molecular testing, have vastly improved the ability to detect these cancers in their earlier stages, significantly improving patient outcomes. Imaging technologies such as PET, MRI, and CT scans are widely used to identify and monitor tumors, providing detailed insights into the location and extent of cancer spread. Additionally, molecular diagnostics are transforming the landscape of head and neck cancer diagnostics by identifying specific genetic mutations and biomarkers linked to these cancers. Technologies such as liquid biopsy, which can detect circulating tumor DNA in the blood, offer less invasive alternatives to traditional tissue biopsies, allowing for earlier detection and more personalized treatment options. These advancements are enhancing the precision of diagnoses, helping clinicians choose the most appropriate treatments for individual patients, and improving survival rates in the process.

What Innovations Are Shaping the Future of Head and Neck Cancer Diagnostics?

Technological innovations continue to drive the evolution of head and neck cancer diagnostics, making it easier to identify cancer at an early stage and tailor treatments to individual patient needs. One significant advancement is the rise of next-generation sequencing (NGS) technology, which allows for the comprehensive analysis of genetic mutations and abnormalities in tumors. NGS provides detailed information about the cancer’s molecular profile, helping doctors predict how it will respond to different treatments. Another key innovation is artificial intelligence (AI)-driven diagnostic tools, which are being developed to analyze complex datasets, including imaging results and genetic information, to assist clinicians in making faster and more accurate diagnoses. These AI-powered systems can detect patterns that may be missed by the human eye, leading to earlier identification of malignancies. Additionally, point-of-care diagnostics, which enable rapid, on-site testing, are gaining popularity, particularly in regions with limited access to advanced healthcare infrastructure. These technological breakthroughs are propelling head and neck cancer diagnostics towards more personalized and efficient care.

How Are Changing Consumer and Healthcare Trends Impacting the Demand for Head and Neck Cancer Diagnostics?

Consumer awareness and healthcare trends are playing a vital role in shaping the demand for head and neck cancer diagnostics. With an increasing focus on preventive healthcare, patients are more proactive in seeking screenings for cancers, including those of the head and neck, particularly when they fall into high-risk categories such as smokers or individuals exposed to the human papillomavirus (HPV). Rising awareness campaigns around early detection and the dangers of tobacco use have prompted a greater number of individuals to seek diagnostic services, particularly in developed regions with robust healthcare systems. Moreover, the aging global population is contributing to the rise in head and neck cancer cases, as these cancers are more common in older adults. As healthcare providers place more emphasis on early diagnosis to improve patient outcomes and reduce the cost of late-stage treatments, the demand for comprehensive diagnostic services continues to increase, driving growth in this market.

What Factors Are Driving Growth in the Head and Neck Cancer Diagnostics Market?

The growth in the head and neck cancer diagnostics market is driven by several factors related to technological advancements, rising cancer incidence, and evolving healthcare policies. One of the primary drivers is the increasing adoption of advanced diagnostic technologies such as liquid biopsy, next-generation sequencing, and AI-powered imaging, which allow for earlier and more accurate cancer detection. The rising incidence of head and neck cancers, particularly those linked to HPV, has also expanded the market's scope, as healthcare providers and governments focus on screening initiatives. End-use applications are growing as hospitals, diagnostic centers, and research institutes adopt these technologies to meet the demand for precise and non-invasive cancer detection. Additionally, the shift towards personalized medicine, which emphasizes treatment plans tailored to the genetic makeup of a patient’s tumor, is boosting the need for molecular diagnostics. Regulatory frameworks promoting early cancer detection and the global rise in healthcare expenditures are further accelerating the adoption of advanced diagnostics, making this an expanding and rapidly evolving market.

Select Competitors (Total 53 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â